<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Minimal change disease: Etiology, clinical features, and diagnosis in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Minimal change disease: Etiology, clinical features, and diagnosis in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Minimal change disease: Etiology, clinical features, and diagnosis in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alain Meyrier, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jai Radhakrishnan, MD, MS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 01, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Minimal change disease (MCD) is a major cause of the nephrotic syndrome in children (approximately 90 percent) and in a minority of adults (approximately 10 percent). MCD and primary focal segmental glomerulosclerosis (FSGS) are both examples of pathogenic mechanisms that predominantly affect the podocyte ("podocytopathies").</p><p>The epidemiology, pathogenesis, etiology, clinical features, and diagnosis of MCD in adults will be reviewed here. Other aspects of MCD, including the treatment of MCD in adults, the diagnosis and treatment of MCD in children, and acute kidney injury (AKI) in MCD are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3047.html" rel="external">"Acute kidney injury (AKI) in minimal change disease and other forms of nephrotic syndrome"</a>.)</p><p></p><p class="headingAnchor" id="H962011923"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Although minimal change disease (MCD) is the most common cause of the nephrotic syndrome in children, MCD also accounts for a smaller proportion of cases of the nephrotic syndrome in adults. In a study published in 1987, MCD was present in 10 to 15 percent of cases of adult nephrotic syndrome [<a href="#rid1">1</a>]. The percentage of nephrotic adults with MCD has since decreased [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Primary nephrotic syndrome'</a>.)</p><p>In addition to age, ethnicity is an important predictor of the percentage of nephrotic patients with MCD, although epidemiologic studies may be confounded by prevailing ethnic differences in the studied populations. The percentage of nephrotic patients with MCD is highest in Asian populations and White populations, while the percentage of nephrotic patients with underlying focal segmental glomerulosclerosis (FSGS) lesions (mostly genetic and related to <em>APOL1</em> high-risk alleles) is highest in African American populations [<a href="#rid3">3,4</a>].</p><p class="headingAnchor" id="H3174127220"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The underlying cause of minimal change disease (MCD) is unclear. Accumulating evidence suggests that systemic T cell dysfunction results in the production of a glomerular permeability factor. This circulating factor directly affects the glomerular capillary wall, resulting in marked proteinuria and foot process effacement. In a subset of patients with MCD, autoantibodies targeting the slit diaphragm component nephrin may contribute to the pathogenesis of disease.</p><p class="headingAnchor" id="H2175371595"><span class="h2">T cell dysfunction</span><span class="headingEndMark"> — </span>The following observations are consistent with the hypothesis that cell-mediated immunity is a major pathogenic factor in MCD [<a href="#rid5">5</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Remission can be induced by measles, an infection known to modify cell-mediated immunity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children with glucocorticoid-sensitive nephrotic syndrome, relapses were associated with a decrease in T regulatory cells [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The lesion of MCD occurs more frequently in patients with Hodgkin lymphoma than in the general population. (See <a class="local">'Malignancies'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atopic individuals are at higher risk for the development of MCD. (See <a class="local">'Allergy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, which modify cell-mediated responses, have proven benefit in the treatment of MCD. (See  <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults"</a>.)</p><p></p><p>Immature and relatively undifferentiated T cells (CD34+) rather than mature T cells (CD34-) have been implicated in the pathogenesis of MCD. In an animal study, for example, proteinuria and foot process effacement were observed in non-obese diabetic severe combined immunodeficient (NOD/SCID) mice after the engraftment of CD34+ but not CD34- cells harvested from patients with either glucocorticoid-sensitive MCD or focal segmental glomerulosclerosis (FSGS) [<a href="#rid7">7</a>].</p><p>Regulatory T cells may also play a role in the pathogenesis of MCD. In animal models of the nephrotic syndrome, depletion of peripheral regulatory T cells has been observed, and these cells repopulate in the setting of disease remission [<a href="#rid8">8</a>]. Furthermore, the administration of L15-0195 (a deoxyspergualin [a synthetic analogue of the immunosuppressive antitumor antibiotic spergualin] derivative) induces regulatory T cells that can induce regression of nephropathy in rats [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H1242679848"><span class="h2">Glomerular permeability factor</span><span class="headingEndMark"> — </span>A variety of observations support the possibility that a circulating factor of immune origin alters glomerular permeability in MCD, thereby resulting in proteinuria [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A T cell hybridoma made from a patient with MCD released a substance that, when injected into rats, induced proteinuria and foot process effacement [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/3068.html" rel="external">"Mechanisms of immune injury of the glomerulus"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an in vitro assay using isolated rat glomeruli, increased permeability to albumin was noted after incubation with sera collected from a patient with MCD and Hodgkin lymphoma [<a href="#rid11">11</a>]. Serum permeability activity did not change in response to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> but was markedly decreased by induction of remission of Hodgkin lymphoma by chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two kidneys from a patient with MCD were inadvertently transplanted into two recipients without significant baseline proteinuria [<a href="#rid12">12</a>]. In both recipients, proteinuria was present at the time of grafting but diminished rapidly and was within the normal range within six weeks.</p><p></p><p>The identity of the glomerular permeability factor in MCD has not been determined in humans. However, accruing data have implicated T helper type 2 (Th2)-derived cytokines, particularly interleukin (IL) 13 [<a href="#rid13">13-19</a>]. In rats, for example, systemic overexpression of IL-13 results in albuminuria, hypoalbuminemia, and on kidney biopsy, up to 80 percent podocyte foot process fusion by electron microscopy and no significant histologic changes by light microscopy (pathologic findings similar to those in MCD) [<a href="#rid19">19</a>]. Another candidate protein for a permeability factor is the circulating heme scavenger hemopexin. Usually inactive, hemopexin may become activated as a serine protease, leading to nephrin-dependent cytoskeletal rearrangement in podocytes and changes in permeability of the glomerular filtration barrier by a reduction in glycocalyx [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H2377956170"><span class="h2">Role of B cells</span><span class="headingEndMark"> — </span>The role of B cells in the pathophysiology of MCD was, for many years, considered negligible. However, studies on the favorable effect on MCD of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, a chimeric monoclonal antibody that depletes the CD20+ B cell population, suggest that a glomerular permeability factor could be produced by B cells or T cells through pathways regulated or stimulated by B cells [<a href="#rid21">21</a>]. These results of MCD treatment with rituximab suggest a role for B cells in addition to T cells in the pathogenesis of MCD in some patients. Because rituximab appears to be effective in glucocorticoid-responsive but not glucocorticoid-resistant MCD, glucocorticoid sensitivity and resistance might reflect different pathogenic pathways. (See  <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults", section on 'Rituximab'</a>.)</p><p>Antibodies targeting nephrin, an essential component of the slit diaphragm, have been shown to cause massive proteinuria when administered in animal models [<a href="#rid22">22,23</a>] and may contribute to the pathogenesis of MCD in a subset of human patients [<a href="#rid24">24,25</a>]. In a study of 62 adults and children with biopsy-proven MCD and no known genetic basis, circulating anti-nephrin antibodies were identified in 18 (29 percent) who had active disease at the time of sampling [<a href="#rid24">24</a>]. Antibody titers were reduced or absent during clinical response to treatment. Immunofluorescence microscopy revealed punctuate immunoglobulin G (IgG) deposits colocalized with nephrin in the kidney biopsies of nine patients, all of whom were serologically positive for anti-nephrin antibodies; no punctate deposits were seen in the biopsies of patients who were serologically negative. One female patient with childhood-onset, glucocorticoid-dependent MCD progressed to FSGS and end-stage kidney disease (ESKD); following kidney transplantation, she rapidly developed recurrent nephrotic syndrome that was associated with high titers of pretransplant circulating anti-nephrin antibodies. With plasmapheresis, she experienced remission accompanied by the disappearance of anti-nephrin antibodies. Collectively, these findings suggest that an autoimmune etiology may be responsible in a subset of patients with MCD.</p><p class="headingAnchor" id="H73323693"><span class="h2">Role of the glomerular basement membrane</span><span class="headingEndMark"> — </span>The mechanism by which a putative circulating factor leads to a compromise of the glomerular capillary wall is incompletely understood. The glomerular capillary wall comprises three structures that separate the capillary lumen from Bowman's space: the fenestrated endothelium, the glomerular basement membrane (GBM), and the epithelium with a slit diaphragm between podocyte foot processes  (<a class="graphic graphic_figure graphicRef120965" href="/z/d/graphic/120965.html" rel="external">figure 1</a>). The endothelium and the GBM are strongly anionic with the electronegative charges being provided by sialic acid and heparan sulfate [<a href="#rid26">26,27</a>]. Under normal circumstances, the negative charge of the GBM repulses circulating albumin molecules since albumin is negatively charged at neutral pH. </p><p>In patients with MCD, a hypothesis to explain proteinuria was that the glomerular permeability factor diminishes the anionic properties of the GBM. Supporting data were derived from some studies in which the sieving components (Bowman's space fluid-to-plasma ratio) of dextrans of various Stokes-Einstein radii and isoelectric points were determined in healthy and nephrotic humans with MCD or membranous nephropathy [<a href="#rid27">27</a>]. The sieving coefficients of anionic dextrans were less than that of neutral dextrans in healthy subjects; by contrast, there was no difference in sieving coefficients of anionic and neutral dextrans in patients with the nephrotic syndrome. </p><p class="headingAnchor" id="H3840016011"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>Most cases of minimal change disease (MCD) are idiopathic (or primary) and are not clearly associated with an underlying disease or event.</p><p>With secondary MCD, the onset of nephrotic syndrome occurs concurrently or following an extraglomerular or glomerular disease process.</p><p class="headingAnchor" id="H4148136979"><span class="h2">Primary MCD</span><span class="headingEndMark"> — </span>MCD that is not clearly associated with an underlying disease or event is considered primary (or idiopathic) MCD. The underlying cause of primary MCD is unclear but is thought to be related to the production of a circulating glomerular permeability factor that directly affects the glomerular capillary wall, resulting in marked proteinuria and foot process effacement. In a subset of patients with primary MCD, autoantibodies targeting the slit diaphragm component nephrin may contribute to the pathogenesis of disease. (See <a class="local">'Glomerular permeability factor'</a> above and <a class="local">'Role of B cells'</a> above.)</p><p class="headingAnchor" id="H4020098503"><span class="h2">Secondary causes</span><span class="headingEndMark"> — </span>MCD is associated with a variety of secondary causes, including drugs, neoplasms, infections, and allergy. Although MCD is not associated with monogenic variants, familial clustering has been occasionally reported [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H59838940"><span class="h3">Drugs</span><span class="headingEndMark"> — </span>Many drugs can induce a nephrotic syndrome with the histopathologic appearance of MCD. Cessation of the offending drug is usually associated with improvement in the nephrotic syndrome. Drugs associated with MCD include the following [<a href="#rid29">29-32</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsteroidal antiinflammatory drugs (NSAIDs) and selective cyclooxygenase (COX) 2 inhibitors. NSAIDs are the most common cause of secondary MCD. (See  <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis", section on 'NSAID-induced AIN and nephrotic syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobial drugs (<a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">ampicillin</a>, rifampicin, cephalosporins).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">Lithium</a>. (See  <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">"Renal toxicity of lithium", section on 'Nephrotic syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9747" href="/z/d/drug information/9747.html" rel="external">D-penicillamine</a> and <a class="drug drug_general" data-topicid="10287" href="/z/d/drug information/10287.html" rel="external">tiopronin</a>. (See  <a class="medical medical_review" href="/z/d/html/3591.html" rel="external">"Wilson disease: Management", section on 'Adverse effects'</a> and  <a class="medical medical_review" href="/z/d/html/7362.html" rel="external">"Cystinuria and cystine stones", section on 'Thiol-containing drugs for resistant disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">Pamidronate</a> and other bisphosphonates [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/2806.html" rel="external">"Risks of therapy with bone antiresorptive agents in patients with advanced malignancy", section on 'Proteinuria and kidney injury'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">Sulfasalazine</a> and 5-aminosalicylic acid derivatives.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trimethadione.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gamma interferon.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mercury exposure in skin-lightening creams [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune checkpoint inhibitors (<a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, <a class="drug drug_general" data-topicid="112994" href="/z/d/drug information/112994.html" rel="external">durvalumab</a>) [<a href="#rid35">35,36</a>]</p><p></p><p class="headingAnchor" id="H1103297610"><span class="h3">Malignancies</span><span class="headingEndMark"> — </span>MCD has been associated with malignancies, particularly hematologic malignancies, such as Hodgkin lymphoma (previously called Hodgkin disease), non-Hodgkin lymphoma, and leukemia [<a href="#rid37">37-40</a>]. In a review of two large series of patients with Hodgkin lymphoma, 0.4 percent had MCD [<a href="#rid37">37</a>].</p><p>In many cases, the underlying hematologic disease is already apparent at the time of onset of the nephrotic syndrome. The degree of proteinuria usually parallels that of the malignancy, with the proteinuria disappearing when remission of the malignancy is obtained with radiotherapy and chemotherapy [<a href="#rid37">37,38,40</a>]. However, there are patients in whom the course of MCD does not correlate with the course of the lymphoma [<a href="#rid39">39</a>].</p><p>In some patients, MCD precedes the discovery of the lymphoma by several months or even years [<a href="#rid37">37-39</a>]. In a review of 21 patients who had both MCD and Hodgkin lymphoma, eight (38 percent) were diagnosed with MCD a median of two years <strong>prior</strong> to the diagnosis of malignancy [<a href="#rid38">38</a>]. Among these eight patients, one was glucocorticoid dependent and four were glucocorticoid resistant, but all entered remission when the lymphoma was successfully treated.</p><p>Solid tumors are more commonly associated with an immune complex-mediated disease such as membranous nephropathy [<a href="#rid40">40</a>]. However, rare cases of MCD associated with solid tumors have been reported. These include thymoma; renal cell carcinoma; mesothelioma; and bronchogenic, colon, bladder, lung, breast, pancreatic, duodenal, and prostate cancer [<a href="#rid30">30,41,42</a>]. In some, but not all, reported cases, ablation of the tumor was followed by remission of the nephrotic syndrome [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H2930457714"><span class="h3">Infections</span><span class="headingEndMark"> — </span>MCD has been associated with infections including syphilis, tuberculosis, <em>Mycoplasma</em>, ehrlichiosis, hepatitis C virus, <em>Echinococcus</em>, and borreliosis (Lyme disease) [<a href="#rid30">30,32,43</a>]. HIV infection is most often associated with a collapsing focal segmental glomerulosclerosis (FSGS), but MCD has been described [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">"Overview of kidney disease in patients with HIV"</a>.)</p><p class="headingAnchor" id="H1213009447"><span class="h3">Allergy</span><span class="headingEndMark"> — </span>A history of allergy has been described in up to 30 percent of cases of MCD [<a href="#rid45">45,46</a>]. Multiple allergens have been reported in association with MCD, including fungi, poison ivy, ragweed and timothy grass pollen, house dust, medusa stings, bee stings, and cat fur. The onset or occurrence of relapses of nephrotic syndrome can be triggered by an allergic reaction or bee sting.</p><p>Limited evidence suggests that relapsing MCD may be due to food allergy in some patients. In a small series, an oligoantigenic (hypoallergenic) diet-induced remission in some patients with glucocorticoid-resistant MCD [<a href="#rid47">47</a>]. However, this finding has not been replicated in other studies.</p><p class="headingAnchor" id="H4032818280"><span class="h3">Association with other glomerular diseases</span><span class="headingEndMark"> — </span>MCD may be associated with mesangial immunoglobulin A (IgA) deposits and mild mesangial proliferation suggesting the concurrence of IgA nephropathy and MCD [<a href="#rid44">44,48-50</a>]. The mechanism underlying this relationship is not understood and may reflect concurrent disease, especially in Asian individuals [<a href="#rid48">48,49</a>]. These patients respond to glucocorticoid therapy with remission of the nephrotic syndrome, but relapses can occur [<a href="#rid44">44,48-50</a>]. (See  <a class="medical medical_review" href="/z/d/html/3112.html" rel="external">"IgA nephropathy: Clinical features and diagnosis", section on 'Associated conditions'</a> and  <a class="medical medical_review" href="/z/d/html/3039.html" rel="external">"IgA nephropathy: Treatment and prognosis", section on 'IgA nephropathy with apparent minimal change disease'</a>.)</p><p>Although the relationship is unclear, there are reports of MCD occurring in association with other glomerular or kidney diseases, including systemic lupus erythematosus ("lupus podocytopathy"), new-onset type 1 diabetes, and HIV nephropathy [<a href="#rid30">30,51,52</a>]. (See  <a class="medical medical_review" href="/z/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'Lupus podocytopathy'</a>.)</p><p class="headingAnchor" id="H632760296"><span class="h3">Other causes</span><span class="headingEndMark"> — </span>Numerous other, mostly autoimmune, conditions have been described in association with MCD [<a href="#rid30">30</a>]. The mechanisms underlying this association are not identified, and the association may be coincidental rather than causal. These include chronic graft-versus-host disease after hematopoietic cell transplantation, sclerosing cholangitis, sarcoidosis, Graves' disease, thyroiditis, vasculitis, myasthenia gravis, Guillain-Barré syndrome, dermatitis herpetiformis, primary biliary cholangitis, antiphospholipid syndrome, and stiff-person syndrome [<a href="#rid30">30,53-56</a>].</p><p>Cases of MCD following immunizations, including after administration of an mRNA SARS-CoV-2 vaccine [<a href="#rid57">57</a>], have been described. (See  <a class="medical medical_review" href="/z/d/html/127552.html" rel="external">"COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'COVID-19 vaccine-associated glomerular disease'</a>.)</p><p class="headingAnchor" id="H1208062648"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H2882744226"><span class="h2">Typical presentation</span><span class="headingEndMark"> — </span>In most patients, minimal change disease (MCD) is characterized by the sudden onset over days to a week or two of the signs and symptoms of the nephrotic syndrome, often following an upper respiratory or systemic infection. The nephrotic syndrome is characterized by the constellation of proteinuria, mostly albuminuria (almost always greater than 3.5 to 4.0 g/day and occasionally more than 15 to 20 g/day); weight gain and then edema; and on laboratory testing, hypoalbuminemia (serum albumin that may be less than 1.5 to 2.0 g/dL) and, in most cases, hyperlipidemia. (See  <a class="medical medical_review" href="/z/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome"</a>.)</p><p>The typically sudden onset of nephrotic syndrome in MCD is in contrast to the gradual increase in proteinuria over weeks to months in most other causes of nephrotic syndrome such as membranous nephropathy and most variants of focal segmental glomerulosclerosis (FSGS), with the exception of the glomerular tip variant. The sudden onset of nephrotic syndrome is reasonably specific but not very sensitive for MCD in adults and should <strong>not</strong> be used to avoid performing a kidney biopsy to confirm the diagnosis. (See <a class="local">'Diagnosis'</a> below.)</p><p>Other kidney manifestations that may be seen in patients with MCD include:</p><p class="bulletIndent1"><span class="glyph">●</span>Microscopic hematuria is common in adults with MCD and occurs in 20 to 25 percent of children but is not associated with a difference in clinical course [<a href="#rid45">45,58,59</a>]. (See  <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Additional laboratory evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The serum creatinine concentration may be modestly (30 to 40 percent) elevated at presentation in both adults and children. Acute kidney injury (AKI) is an infrequent complication that has been primarily described in adults. (See  <a class="medical medical_review" href="/z/d/html/3047.html" rel="external">"Acute kidney injury (AKI) in minimal change disease and other forms of nephrotic syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Additional laboratory evaluation'</a>.)</p><p></p><p>The clinical findings at presentation in adults with MCD were illustrated in a retrospective analysis of 95 patients [<a href="#rid58">58</a>]. The following findings were noted; the age and laboratory results represent mean values:</p><p class="bulletIndent1"><span class="glyph">●</span>Age – 45 years</p><p class="bulletIndent1"><span class="glyph">●</span>Serum creatinine – 1.4 mg/dL (124 micromol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Estimated glomerular filtration rate (eGFR) – 72 mL/min per 1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>Proteinuria – 9.9 g/day</p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria – 29 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Serum albumin – 2.2 g/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Serum cholesterol – 421 mg/dL (10.9 mmol/L)</p><p class="bulletIndent1"><span class="glyph">●</span>Hypertension – 43 percent </p><p class="bulletIndent1"><span class="glyph">●</span>AKI – 18 percent</p><p></p><p>In addition to the above findings, the nephrotic syndrome can be associated with the following complications, the pathogenesis and manifestations of which are discussed in detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased risk of thromboembolism (see  <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">"Hypercoagulability in nephrotic syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children", section on 'Thromboembolism'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased susceptibility to infection, particularly with encapsulated organisms, which is best described in children (see  <a class="medical medical_review" href="/z/d/html/6102.html" rel="external">"Complications of nephrotic syndrome in children", section on 'Bacterial infection'</a> and  <a class="medical medical_review" href="/z/d/html/3084.html" rel="external">"Overview of heavy proteinuria and the nephrotic syndrome", section on 'Infection'</a>)</p><p></p><p class="headingAnchor" id="H2406404405"><span class="h2">Pathologic findings</span><span class="headingEndMark"> — </span>On kidney biopsy, the glomeruli appear normal by light microscopy, and there are no complement or immunoglobulin deposits on immunofluorescence microscopy. Glomerular size is usually normal by standard methods of light microscopy, although enlarged glomeruli may be observed [<a href="#rid60">60</a>].</p><p>The characteristic histologic lesion in MCD is diffuse effacement (&gt;80 percent; also called "fusion") of the epithelial foot processes on electron microscopy  (<a class="graphic graphic_picture graphicRef58414" data-inline-graphics="58414" href="/z/d/graphic/58414.html" rel="external">picture 1</a>). More specifically, there is retraction, widening, and shortening of the foot processes [<a href="#rid61">61,62</a>]. The spaces between flattened podocyte foot processes are reduced in number, which may play a role in the excess albumin load into the urinary space [<a href="#rid63">63</a>]. The degree of effacement does not correlate with the degree of proteinuria [<a href="#rid64">64</a>]. Foot processes regain a normal appearance with remission of proteinuria.</p><p class="headingAnchor" id="H1445427790"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H4031350957"><span class="h2">When to suspect MCD</span><span class="headingEndMark"> — </span>The diagnosis of minimal change disease (MCD) should be suspected in any adult patient presenting with symptoms and signs of the nephrotic syndrome, especially if the onset is relatively acute (over days to a week or two).</p><p>All patients presenting with the nephrotic syndrome should undergo a thorough evaluation for glomerular disease and other disorders, which generally involves laboratory testing and, in most patients, a kidney biopsy to obtain a definitive diagnosis  (<a class="graphic graphic_algorithm graphicRef113287" data-inline-graphics="113287" href="/z/d/graphic/113287.html" rel="external">algorithm 1</a>). The general evaluation of proteinuria and nephrotic syndrome in adults is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults", section on 'Nephrotic syndrome (heavy proteinuria and hypoalbuminemia)'</a>.)</p><p class="headingAnchor" id="H3434765502"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>A kidney biopsy is required to establish the diagnosis of MCD in adults and to exclude other causes of the nephrotic syndrome. There are no specific laboratory findings that can be used to distinguish MCD from other forms of nephrotic syndrome. (See <a class="local">'Pathologic findings'</a> above.)</p><p>In children, a presumptive diagnosis of MCD is usually made based upon the clinical findings at presentation and the high prevalence of MCD as a cause of the nephrotic syndrome, particularly in children under the age of 10 years. Pediatricians usually restrict kidney biopsy to individuals with glucocorticoid-resistant nephrotic syndrome. (See  <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Decision to biopsy'</a> and  <a class="medical medical_review" href="/z/d/html/6101.html" rel="external">"Clinical manifestations, diagnosis, and evaluation of nephrotic syndrome in children", section on 'Confirming the diagnosis'</a>.)</p><p>Adult patients who are found to have MCD on kidney biopsy should be evaluated for potential underlying secondary causes, particularly malignancy (eg, Hodgkin lymphoma and thymoma) and drug exposures (eg, nonsteroidal antiinflammatory drugs [NSAIDs], <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">pamidronate</a>).</p><p class="headingAnchor" id="H263816993"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>As mentioned above, minimal change disease (MCD) is characterized pathologically by normal-appearing glomeruli on light microscopy and the absence of complement or immunoglobulin deposits on immunofluorescence microscopy. The characteristic histologic lesion is diffuse effacement of the epithelial foot processes on electron microscopy  (<a class="graphic graphic_picture graphicRef58414" href="/z/d/graphic/58414.html" rel="external">picture 1</a>). Although diffuse foot process effacement is also seen in other causes of the nephrotic syndrome (eg, primary focal segmental glomerulosclerosis [FSGS], membranous nephropathy, diabetic kidney disease, and amyloidosis), these disorders have characteristic findings on light and immunofluorescence microscopy and, in some disorders, blood test abnormalities that are not seen in MCD. (See <a class="local">'Pathologic findings'</a> above and  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p class="headingAnchor" id="H4179980099"><span class="h2">Distinguishing MCD from primary FSGS</span><span class="headingEndMark"> — </span>There continues to be debate as to whether MCD and focal segmental glomerulosclerosis (FSGS) fall within the spectrum of the same disease or whether they represent separate pathogenic entities [<a href="#rid65">65</a>]. Other than the descriptive changes on light microscopy, the two entities can be separated based on clinical and pathological features:</p><p class="bulletIndent1"><span class="glyph">●</span>On one hand, primary MCD is characterized by the full nephrotic syndrome, complete foot process effacement on electron microscopy, and a complete response to immunosuppression (albeit with a significant chance of recurrence). Although patients may present with acute kidney injury (AKI), they usually recover, and end-stage kidney disease (ESKD) is distinctly rare.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FSGS, on the other hand, is now a descriptive term for sclerotic glomerular lesions. There are several pathogenic mechanisms associated with the FSGS lesion (eg, permeability factor related, genetic, hyperfiltration, maladaption for nephron loss, drug or viral injury). In the absence of these associations ("secondary forms of FSGS"), the patients are labeled as having "primary" FSGS, some of which has been ascribed to circulating factor(s) owing to the recurrence of the disease in kidney transplants. Importantly in primary FSGS, response to immunosuppression is seen only in approximately one-half of patients, typically partial remissions (with the exception of the tip lesion [<a href="#rid66">66</a>]), and progressive kidney failure is common in patients with persistent, high-grade proteinuria. (See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis"</a>.)</p><p></p><p>With primary FSGS, the biopsy diagnosis requires the finding of segmental glomerulosclerosis in at least one glomerulus in addition to diffuse foot process effacement. However, sclerotic lesions are focal, and affected glomeruli may be missed, leading to an incorrect diagnosis of MCD. As an example, sclerotic changes occur first in the juxtamedullary glomeruli, which may not be present in superficial biopsies that contain only the outer cortex or in biopsies that contain fewer than eight glomeruli, where sampling error may be important.</p><p>Specific biomarkers have been proposed separating MCD from FSGS, including podocyte B7-1, dystroglycan, angiopoietin-like 4 (Angptl4), urinary CD80, and anti-CD44. Similarly, circulating factors including cardiotrophin-like cytokine factor-1 (CLCF1), soluble urokinase receptor (suPAR), and hemopexin have also been suggested as being specific. Finally, differential gene expression in the glomeruli has been reported. However, these reports have not shown consistent results or have not been validated by other investigators [<a href="#rid65">65</a>].</p><p>Lastly, there are clear examples of patients who begin with a classic, clinical presentation of MCD but over time become increasingly refractory to immunosuppression and, on repeat kidney biopsy, show sclerotic lesions [<a href="#rid67">67,68</a>]. (See  <a class="medical medical_review" href="/z/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults", section on 'Role of repeat kidney biopsy'</a>.)</p><p>It has been postulated that MCD may follow mild injury to the podocyte, which is then followed by complete recovery in the majority of patients. If the injury is severe or if repair mechanisms are defective (eg, in the presence of genetic predisposing factors such as the presence of two high-risk <em>APOL1</em> alleles), podocyte loss occurs, leading to sclerosis and the appearance of FSGS lesions. The latter is associated with less glucocorticoid sensitivity and progressive kidney function impairment [<a href="#rid65">65</a>]. However, it is likely that MCD and FSGS are two separate entities, and the observation that MCD lesions "progress" to FSGS may merely reflect the fact that a biopsy performed early may not reveal sclerosis since the latter phenomenon takes time to occur [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H4002207536"><span class="h2">Minimal change variants</span><span class="headingEndMark"> — </span>In addition to MCD, there are three other disorders that usually present with the nephrotic syndrome and that may show only minor changes on light microscopy: idiopathic mesangial proliferative glomerulonephritis, immunoglobulin M (IgM) nephropathy, and C1q nephropathy. These disorders may represent variants of MCD or FSGS lesions, but some clinicians believe that they may be separate conditions. Regardless of nomenclature, the finding of these variants on a kidney biopsy of an adult with nephrotic syndrome is often associated with a poorer prognosis than that of patients with classic MCD.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic mesangial proliferative glomerulonephritis</strong> – Idiopathic mesangial proliferative glomerulonephritis is characterized by mesangial proliferation and the absence of IgG or IgA immune deposits (though IgM deposits may be present). Patients may have isolated hematuria or nephrotic range proteinuria [<a href="#rid69">69,70</a>]. Whereas the kidney prognosis is favorable for patients with isolated hematuria [<a href="#rid69">69,71</a>], it is not as good for those with nephrotic syndrome, as 10 to 30 percent may develop progressive kidney function impairment [<a href="#rid72">72-75</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>IgM nephropathy</strong> – IgM deposits may be found in patients with MCD, FSGS, and mesangial proliferative glomerulonephritis. Some experts, however, believe that IgM nephropathy is a distinct entity characterized by mesangial proliferation and prominent mesangial deposits of IgM and complement [<a href="#rid70">70,71,76</a>]. Others require the presence of electron dense deposits by electron microscopy as well as the finding of IgM deposition by immunofluorescence microscopy to define IgM nephropathy. The presence of IgM deposits in a patient with MCD signifies a poorer prognosis compared with MCD without deposits, as fewer than 50 percent of such patients respond to glucocorticoids [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>C1q nephropathy</strong> – C1q nephropathy is characterized by mesangial proliferation, mesangial deposits on electron microscopy, and prominent C1q deposits on immunofluorescence microscopy in a patient with no clinical or laboratory evidence of systemic lupus erythematosus [<a href="#rid77">77-82</a>]. C1q nephropathy may be associated with MCD, FSGS, or proliferative glomerulonephritis. The treatment of C1q nephropathy is the same as it is for MCD or FSGS with no C1q deposits.</p><p></p><p class="headingAnchor" id="H520364371"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Minimal change disease (MCD) is a major cause of the nephrotic syndrome in children (approximately 90 percent) and in a minority of adults (approximately 10 percent). MCD and focal segmental glomerulosclerosis (FSGS) are both examples of pathogenic mechanisms that primarily affect the podocyte ("podocytopathies"). (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The underlying cause of MCD is unclear. Accumulating evidence suggests that systemic T cell dysfunction results in the production of a glomerular permeability factor. This circulating factor directly affects the glomerular capillary wall, resulting in marked proteinuria and foot process effacement. There is emerging evidence for the role of B cells and anti-nephrin antibodies in the pathogenesis of MCD. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Most cases of MCD are idiopathic (or primary) and are not clearly associated with an underlying disease or event. With secondary MCD, the onset of nephrotic syndrome occurs concurrently or following an extraglomerular or glomerular disease process. MCD is associated with a variety of secondary causes, including drugs, neoplasms, infections, and allergy. (See <a class="local">'Etiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – In most patients, MCD is characterized by the sudden onset over days to a week or two of the signs and symptoms of the nephrotic syndrome, often following an upper respiratory or systemic infection. The typically sudden onset of nephrotic syndrome in MCD is in contrast to the gradual increase in proteinuria over weeks to months in most other causes of nephrotic syndrome. Microscopic hematuria and acute kidney injury (AKI) may also be seen in adults with MCD. Histologically, MCD is characterized by normal-appearing glomeruli by light microscopy and the absence of complement or immunoglobulin deposits by immunofluorescence microscopy. The characteristic histologic lesion in MCD is diffuse effacement of the podocyte foot processes on electron microscopy. (See <a class="local">'Typical presentation'</a> above and <a class="local">'Pathologic findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of MCD should be suspected in any adult patient presenting with symptoms and signs of the nephrotic syndrome, especially if the onset is relatively acute (over days to a week or two). A kidney biopsy is required to establish the diagnosis of MCD in adults and to exclude other causes of the nephrotic syndrome. There are no specific laboratory findings that can be used to distinguish MCD from other forms of nephrotic syndrome. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of MCD in adults includes disorders that also may present with the acute onset of the nephrotic syndrome, such as the glomerular tip lesion variant of FSGS; that are characterized by the combination of the nephrotic syndrome and AKI; or that have foot process effacement on kidney biopsy. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cameron JS. The nephrotic syndrome and its complications. Am J Kidney Dis 1987; 10:157.</a></li><li><a class="nounderline abstract_t">Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30:621.</a></li><li><a class="nounderline abstract_t">Srivastava T, Simon SD, Alon US. High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood. Pediatr Nephrol 1999; 13:13.</a></li><li><a class="nounderline abstract_t">Feehally J, Kendell NP, Swift PG, Walls J. High incidence of minimal change nephrotic syndrome in Asians. Arch Dis Child 1985; 60:1018.</a></li><li><a class="nounderline abstract_t">Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974; 2:556.</a></li><li><a class="nounderline abstract_t">Le Berre L, Bruneau S, Naulet J, et al. Induction of T regulatory cells attenuates idiopathic nephrotic syndrome. J Am Soc Nephrol 2009; 20:57.</a></li><li><a class="nounderline abstract_t">Sellier-Leclerc AL, Duval A, Riveron S, et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 2007; 18:2732.</a></li><li><a class="nounderline abstract_t">Bertelli R, Bonanni A, Di Donato A, et al. Regulatory T cells and minimal change nephropathy: in the midst of a complex network. Clin Exp Immunol 2016; 183:166.</a></li><li><a class="nounderline abstract_t">Maas RJ, Deegens JK, Wetzels JF. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transplant 2014; 29:2207.</a></li><li><a class="nounderline abstract_t">Koyama A, Fujisaki M, Kobayashi M, et al. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40:453.</a></li><li><a class="nounderline abstract_t">Aggarwal N, Batwara R, McCarthy ET, et al. Serum permeability activity in steroid-resistant minimal change nephrotic syndrome is abolished by treatment of Hodgkin disease. Am J Kidney Dis 2007; 50:826.</a></li><li><a class="nounderline abstract_t">Ali AA, Wilson E, Moorhead JF, et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 1994; 58:849.</a></li><li><a class="nounderline abstract_t">Cheung W, Wei CL, Seah CC, et al. Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome. Pediatr Nephrol 2004; 19:627.</a></li><li><a class="nounderline abstract_t">Yap HK, Cheung W, Murugasu B, et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999; 10:529.</a></li><li><a class="nounderline abstract_t">Van Den Berg JG, Aten J, Chand MA, et al. Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells. J Am Soc Nephrol 2000; 11:413.</a></li><li><a class="nounderline abstract_t">Ishimoto T, Shimada M, Araya CE, et al. Minimal change disease: a CD80 podocytopathy? Semin Nephrol 2011; 31:320.</a></li><li><a class="nounderline abstract_t">Van Den Berg JG, Aten J, Annink C, et al. Interleukin-4 and -13 promote basolateral secretion of H(+) and cathepsin L by glomerular epithelial cells. Am J Physiol Renal Physiol 2002; 282:F26.</a></li><li><a class="nounderline abstract_t">Kimata H, Fujimoto M, Furusho K. Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome. Eur J Immunol 1995; 25:1497.</a></li><li><a class="nounderline abstract_t">Lai KW, Wei CL, Tan LK, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007; 18:1476.</a></li><li><a class="nounderline abstract_t">Lennon R, Singh A, Welsh GI, et al. Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol 2008; 19:2140.</a></li><li><a class="nounderline abstract_t">Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transplant 2008; 23:377.</a></li><li><a class="nounderline abstract_t">Orikasa M, Matsui K, Oite T, Shimizu F. Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody. J Immunol 1988; 141:807.</a></li><li><a class="nounderline abstract_t">Takeuchi K, Naito S, Kawashima N, et al. New Anti-Nephrin Antibody Mediated Podocyte Injury Model Using a C57BL/6 Mouse Strain. Nephron 2018; 138:71.</a></li><li><a class="nounderline abstract_t">Watts AJB, Keller KH, Lerner G, et al. Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. J Am Soc Nephrol 2022; 33:238.</a></li><li><a class="nounderline abstract_t">Patrakka J, Ruotsalainen V, Reponen P, et al. Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin. Transplantation 2002; 73:394.</a></li><li><a class="nounderline abstract_t">Carrie BJ, Salyer WR, Myers BD. Minimal change nephropathy: an electrochemical disorder of the glomerular membrane. Am J Med 1981; 70:262.</a></li><li><a class="nounderline abstract_t">Guasch A, Deen WM, Myers BD. Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans. J Clin Invest 1993; 92:2274.</a></li><li><a class="nounderline abstract_t">Chehade H, Cachat F, Girardin E, et al. Two new families with hereditary minimal change disease. BMC Nephrol 2013; 14:65.</a></li><li><a class="nounderline abstract_t">Almansori M, Kovithavongs T, Qarni MU. Cyclooxygenase-2 inhibitor-associated minimal-change disease. Clin Nephrol 2005; 63:381.</a></li><li><a class="nounderline abstract_t">Glassock RJ. Secondary minimal change disease. Nephrol Dial Transplant 2003; 18 Suppl 6:vi52.</a></li><li><a class="nounderline abstract_t">Lecoules S, Duvic C, Hérody M, Nédélec G. [Tiopronin-induced nephrotic syndrome with minimal glomerular lesions]. Presse Med 1999; 28:273.</a></li><li><a class="nounderline abstract_t">Aoyama M, Sugimoto T, Yokono T, et al. Minimal-change nephropathy and chronic hepatitis C infection: coincidental or associated? Nephrol Dial Transplant 2007; 22:1479.</a></li><li><a class="nounderline abstract_t">Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004; 65:634.</a></li><li><a class="nounderline abstract_t">Tang HL, Mak YF, Chu KH, et al. Minimal change disease caused by exposure to mercury-containing skin lightening cream: a report of 4 cases. Clin Nephrol 2013; 79:326.</a></li><li><a class="nounderline abstract_t">Toda MG, Fujii K, Kato A, et al. Minimal Change Disease Associated With Durvalumab. Kidney Int Rep 2021; 6:2733.</a></li><li><a class="nounderline abstract_t">Kitchlu A, Jhaveri KD, Wadhwani S, et al. A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep 2021; 6:66.</a></li><li><a class="nounderline abstract_t">Dabbs DJ, Striker LM, Mignon F, Striker G. Glomerular lesions in lymphomas and leukemias. Am J Med 1986; 80:63.</a></li><li><a class="nounderline abstract_t">Audard V, Larousserie F, Grimbert P, et al. Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature. Kidney Int 2006; 69:2251.</a></li><li><a class="nounderline abstract_t">Korzets Z, Golan E, Manor Y, et al. Spontaneously remitting minimal change nephropathy preceding a relapse of Hodgkin's disease by 19 months. Clin Nephrol 1992; 38:125.</a></li><li><a class="nounderline abstract_t">Alpers CE, Cotran RS. Neoplasia and glomerular injury. Kidney Int 1986; 30:465.</a></li><li><a class="nounderline abstract_t">Meyrier A, Delahousse M, Callard P, Rainfray M. Minimal change nephrotic syndrome revealing solid tumors. Nephron 1992; 61:220.</a></li><li><a class="nounderline abstract_t">Auguet T, Lorenzo A, Colomer E, et al. Recovery of minimal change nephrotic syndrome and acute renal failure in a patient withRenal cell carcinoma. Am J Nephrol 1998; 18:433.</a></li><li><a class="nounderline abstract_t">Kwiatkowska E, Gołembiewska E, Ciechanowski K, Kędzierska K. Minimal-Change Disease Secondary to Borrelia burgdorferi Infection. Case Rep Nephrol 2012; 2012:294532.</a></li><li><a class="nounderline abstract_t">Boix E, Rivera F, Gil CM, et al. Steroid-responsive nephrotic syndrome with minimal-change disease and IgA deposits in a HIV-infected patient. Nephrol Dial Transplant 2000; 15:412.</a></li><li class="breakAll">Niaudet P, Meyrier A. Minimal change disease: clinical features and diagnosis. In: Oxford Textbook of Clinical Nephrology, 4th ed, Turner N, Lameire N, Goldsmith DJ, et al (Eds), Oxford University Press, Oxford 2016. Vol 1, p.501.</li><li><a class="nounderline abstract_t">Abdel-Hafez M, Shimada M, Lee PY, et al. Idiopathic nephrotic syndrome and atopy: is there a common link? Am J Kidney Dis 2009; 54:945.</a></li><li><a class="nounderline abstract_t">Lagrue G, Laurent J, Rostoker G. Food allergy and idiopathic nephrotic syndrome. Kidney Int Suppl 1989; 27:S147.</a></li><li><a class="nounderline abstract_t">Lai KN, Lai FM, Chan KW, et al. An overlapping syndrome of IgA nephropathy and lipoid nephrosis. Am J Clin Pathol 1986; 86:716.</a></li><li><a class="nounderline abstract_t">Cheng IK, Chan KW, Chan MK. Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission. Am J Kidney Dis 1989; 14:361.</a></li><li><a class="nounderline abstract_t">Westhoff TH, Waldherr R, Loddenkemper C, et al. Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease? Clin Nephrol 2006; 65:203.</a></li><li><a class="nounderline abstract_t">Dube GK, Markowitz GS, Radhakrishnan J, et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol 2002; 57:120.</a></li><li><a class="nounderline abstract_t">Nishizono R, Kogou H, Ishizaki Y, et al. Concurrent minimal change nephrotic syndrome and type 1 diabetes mellitus in an adult Japanese woman: a case report. BMC Nephrol 2020; 21:410.</a></li><li><a class="nounderline abstract_t">Rao PS. Nephrotic syndrome in patients with peripheral blood stem cell transplant. Am J Kidney Dis 2005; 45:780.</a></li><li><a class="nounderline abstract_t">Lai TS, Lin WC, Wu MS, et al. Primary biliary cirrhosis associated with minimal change disease. Nephrol Dial Transplant 2007; 22:966.</a></li><li><a class="nounderline abstract_t">Rossiñol T, Cervera R, López C, et al. Antiphospholipid syndrome and minimal change nephropathy. Lupus 2006; 15:547.</a></li><li><a class="nounderline abstract_t">Ergün I, Akbostanci MC, Canbakan B, et al. Minimal change nephrotic syndrome with stiff-person syndrome: is there a link? Am J Kidney Dis 2005; 46:e11.</a></li><li><a class="nounderline abstract_t">Salem F, Rein JL, Yu SM, et al. Report of Three Cases of Minimal Change Disease Following the Second Dose of mRNA SARS-CoV-2 COVID-19 Vaccine. Kidney Int Rep 2021; 6:2523.</a></li><li><a class="nounderline abstract_t">Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol 2007; 2:445.</a></li><li><a class="nounderline abstract_t">Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 1978; 13:159.</a></li><li><a class="nounderline abstract_t">Fogo A, Hawkins EP, Berry PL, et al. Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis. Kidney Int 1990; 38:115.</a></li><li class="breakAll">Schnaper HW, Robson AA, Kopp JB. Nephrotic syndrome: Minimal change nephropathy, focal segmental glomerulosclerosis, and collapsing glomerulopathy. In: Diseases of the Kidney and Urinary Tract, 8th ed, Schrier RW (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2007. p.1585.</li><li><a class="nounderline abstract_t">Shirato I. Podocyte process effacement in vivo. Microsc Res Tech 2002; 57:241.</a></li><li><a class="nounderline abstract_t">Smithies O. Why the kidney glomerulus does not clog: a gel permeation/diffusion hypothesis of renal function. Proc Natl Acad Sci U S A 2003; 100:4108.</a></li><li><a class="nounderline abstract_t">van den Berg JG, van den Bergh Weerman MA, Assmann KJ, et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004; 66:1901.</a></li><li><a class="nounderline abstract_t">Maas RJ, Deegens JK, Smeets B, et al. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol 2016; 12:768.</a></li><li><a class="nounderline abstract_t">Stokes MB, Markowitz GS, Lin J, et al. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004; 65:1690.</a></li><li><a class="nounderline abstract_t">Hayslett JP, Krassner LS, Bensch KG, et al. Progression of "lipoid nephrosis" to renal insufficiency. N Engl J Med 1969; 281:181.</a></li><li><a class="nounderline abstract_t">Tejani A. Morphological transition in minimal change nephrotic syndrome. Nephron 1985; 39:157.</a></li><li><a class="nounderline abstract_t">Brown EA, Upadhyaya K, Hayslett JP, et al. The clinical course of mesangial proliferative glomerulonephritis. Medicine (Baltimore) 1979; 58:295.</a></li><li><a class="nounderline abstract_t">O'Donoghue DJ, Lawler W, Hunt LP, et al. IgM-associated primary diffuse mesangial proliferative glomerulonephritis: natural history and prognostic indicators. Q J Med 1991; 79:333.</a></li><li><a class="nounderline abstract_t">Border WA. Distinguishing minimal-change disease from mesangial disorders. Kidney Int 1988; 34:419.</a></li><li><a class="nounderline abstract_t">Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1983; 24:87.</a></li><li><a class="nounderline abstract_t">Ji-Yun Y, Melvin T, Sibley R, Michael AF. No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome. Kidney Int 1984; 25:100.</a></li><li><a class="nounderline abstract_t">Waldherr R, Gubler MC, Levy M, et al. The significance of pure diffuse mesangial proliferation in idiopathic nephrotic syndrome. Clin Nephrol 1978; 10:171.</a></li><li><a class="nounderline abstract_t">Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 1981; 20:765.</a></li><li><a class="nounderline abstract_t">Cohen AH, Border WA, Glassock RJ. Nehprotic syndrome with glomerular mesangial IgM deposits. Lab Invest 1978; 38:610.</a></li><li><a class="nounderline abstract_t">Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis 1985; 6:103.</a></li><li><a class="nounderline abstract_t">Iskandar SS, Browning MC, Lorentz WB. C1q nephropathy: a pediatric clinicopathologic study. Am J Kidney Dis 1991; 18:459.</a></li><li><a class="nounderline abstract_t">Markowitz GS, Schwimmer JA, Stokes MB, et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int 2003; 64:1232.</a></li><li><a class="nounderline abstract_t">Sharman A, Furness P, Feehally J. Distinguishing C1q nephropathy from lupus nephritis. Nephrol Dial Transplant 2004; 19:1420.</a></li><li><a class="nounderline abstract_t">Kersnik Levart T, Kenda RB, Avgustin Cavić M, et al. C1Q nephropathy in children. Pediatr Nephrol 2005; 20:1756.</a></li><li><a class="nounderline abstract_t">Devasahayam J, Erode-Singaravelu G, Bhat Z, et al. C1q Nephropathy: The Unique Underrecognized Pathological Entity. Anal Cell Pathol (Amst) 2015; 2015:490413.</a></li></ol></div><div id="topicVersionRevision">Topic 3046 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3307394" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The nephrotic syndrome and its complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9370176" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10100283" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : High incidence of focal segmental glomerulosclerosis in nephrotic syndrome of childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4073934" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : High incidence of minimal change nephrotic syndrome in Asians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4140273" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pathogenesis of lipoid nephrosis: a disorder of T-cell function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19020006" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Induction of T regulatory cells attenuates idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855645" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26147676" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Regulatory T cells and minimal change nephropathy: in the midst of a complex network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416821" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1787645" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A glomerular permeability factor produced by human T cell hybridomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17954296" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serum permeability activity in steroid-resistant minimal change nephrotic syndrome is abolished by treatment of Hodgkin disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7940721" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15064938" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Atopy, serum IgE, and interleukin-13 in steroid-responsive nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073603" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703665" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Interleukin-4 and interleukin-13 act on glomerular visceral epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839364" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Minimal change disease: a CD80 podocytopathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739109" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Interleukin-4 and -13 promote basolateral secretion of H(+) and cathepsin L by glomerular epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7614976" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Involvement of interleukin (IL)-13, but not IL-4, in spontaneous IgE and IgG4 production in nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17429054" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753258" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17981884" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rapid remission of steroid and mycophenolate mofetil (mmf)-resistant minimal change nephrotic syndrome after rituximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3397534" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Massive proteinuria induced in rats by a single intravenous injection of a monoclonal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28965116" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : New Anti-Nephrin Antibody Mediated Podocyte Injury Model Using a C57BL/6 Mouse Strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34732507" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884936" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6162382" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Minimal change nephropathy: an electrochemical disorder of the glomerular membrane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8227342" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23517548" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Two new families with hereditary minimal change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15909598" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cyclooxygenase-2 inhibitor-associated minimal-change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12953043" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Secondary minimal change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073167" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : [Tiopronin-induced nephrotic syndrome with minimal glomerular lesions].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210595" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Minimal-change nephropathy and chronic hepatitis C infection: coincidental or associated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14717935" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Podocyte injury associated glomerulopathies induced by pamidronate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23537684" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Minimal change disease caused by exposure to mercury-containing skin lightening cream: a report of 4 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34622115" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Minimal Change Disease Associated With Durvalumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33426386" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3510541" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Glomerular lesions in lymphomas and leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672913" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1395162" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Spontaneously remitting minimal change nephropathy preceding a relapse of Hodgkin's disease by 19 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3537450" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Neoplasia and glomerular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1321349" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Minimal change nephrotic syndrome revealing solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9730570" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Recovery of minimal change nephrotic syndrome and acute renal failure in a patient withRenal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24527240" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Minimal-Change Disease Secondary to Borrelia burgdorferi Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10692530" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Steroid-responsive nephrotic syndrome with minimal-change disease and IgA deposits in a HIV-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10692530" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Steroid-responsive nephrotic syndrome with minimal-change disease and IgA deposits in a HIV-infected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556042" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Idiopathic nephrotic syndrome and atopy: is there a common link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2484004" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Food allergy and idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3538845" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : An overlapping syndrome of IgA nephropathy and lipoid nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2816928" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Mesangial IgA nephropathy with steroid-responsive nephrotic syndrome: disappearance of mesangial IgA deposits following steroid-induced remission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16550751" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Mesangial IgA deposition in minimal change nephrotic syndrome: coincidence of different entities or variant of minimal change disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11863121" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Minimal change disease in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32967631" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Concurrent minimal change nephrotic syndrome and type 1 diabetes mellitus in an adult Japanese woman: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15806483" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nephrotic syndrome in patients with peripheral blood stem cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17082214" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Primary biliary cirrhosis associated with minimal change disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16942010" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Antiphospholipid syndrome and minimal change nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983949" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Minimal change nephrotic syndrome with stiff-person syndrome: is there a link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34337193" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Report of Three Cases of Minimal Change Disease Following the Second Dose of mRNA SARS-CoV-2 COVID-19 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699450" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adult minimal-change disease: clinical characteristics, treatment, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/713276" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2385079" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2385079" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Glomerular hypertrophy in minimal change disease predicts subsequent progression to focal glomerular sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12012392" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Podocyte process effacement in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12655073" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Why the kidney glomerulus does not clog: a gel permeation/diffusion hypothesis of renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496161" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27748392" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Minimal change disease and idiopathic FSGS: manifestations of the same disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15086908" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5790494" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Progression of "lipoid nephrosis" to renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3974779" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Morphological transition in minimal change nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/449664" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The clinical course of mesangial proliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1852859" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : IgM-associated primary diffuse mesangial proliferative glomerulonephritis: natural history and prognostic indicators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3050250" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Distinguishing minimal-change disease from mesangial disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6620853" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Childhood nephrotic syndrome associated with diffuse mesangial hypercellularity. A report of the Southwest Pediatric Nephrology Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6727121" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : No evidence for a specific role of IgM in mesangial proliferation of idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/365403" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The significance of pure diffuse mesangial proliferation in idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7334749" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/347169" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Nehprotic syndrome with glomerular mesangial IgM deposits.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3875286" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1928065" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : C1q nephropathy: a pediatric clinicopathologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12969141" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : C1q nephropathy: a variant of focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15004260" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Distinguishing C1q nephropathy from lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16247648" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : C1Q nephropathy in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26640759" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : C1q Nephropathy: The Unique Underrecognized Pathological Entity.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
